The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma

Citation

Talaulikar, D, Opat, S, Opat, S et al. 2021, 'The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma', Clinical Cancer Research, vol. 27, no. 23, pp. 6323-6332.

Year

2021

Updated:  15 July 2024 / Responsible Officer:  Director (Research Services Division) / Page Contact:  Researchers